Actively Recruiting
Evaluating Safety and Eye Pressure-Lowering Effect of iDose TR Implant With Cataract Surgery Compared to Surgery Alone in Patients with Open-Angle Glaucoma or Ocular Hypertension
Led by Glaukos Corporation · Updated on 2026-01-21
132
Participants Needed
1
Research Sites
43 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of the iDose TR, a travoprost intracameral implant, when used together with cataract surgery. The study compares this treatment combination to cataract surgery alone in patients with open-angle glaucoma or ocular hypertension. This Phase 4, randomized, double-masked, parallel group trial aims to understand how well the implant lowers intraocular pressure IOP and its safety during cataract surgery. Participants will receive either the iDose TR implant along with cataract surgery or a sham procedure alongside cataract surgery. The cataract surgery used is phacoemulsification with a posterior chamber intraocular lens. The iDose TR implant delivers 75 micrograms of travoprost directly inside the eye during the surgery. The study monitors both groups to assess differences in outcomes. During the trial, participants will be evaluated for changes in their mean diurnal intraocular pressure at three months after treatment. Researchers will monitor safety and IOP-lowering effects throughout. Participants will undergo regular assessments related to their eye health, including measurements of eye pressure. The total duration of involvement and follow-up details are not specified but include the 3-month primary outcome assessment period.
CONDITIONS
Brief Title
Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone
Research Team
S
Study Manager
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here